Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AURORA, Ore., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Life Flight Network (LFN), the largest not-for-profit air medical transport service in the United States, announced it will be opening a base at the...
-
SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for...
-
PHILADELPHIA, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Independence Blue Cross (Independence) today announced that it will present at the 33rd annual J.P. Morgan Healthcare Conference in San Francisco on...
-
LENEXA, Kan., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Mediware Information Systems, Inc. announces that it has entered into an agreement with A/R Allegiance Group, a firm specializing in strategies to...
-
Expects 2015 Revenue of $77-$84 Million Expects 2015 EBITDA of $6.2-$8.0 Million NASHVILLE, Tenn., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Symmetry Surgical Inc. (Nasdaq:SSRG) announced today revenue...
-
LYON, France, Jan. 9, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its Focal One HIFU device has been approved by Health...
-
PHILADELPHIA, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on Thursday, January...
-
RESEARCH TRIANGLE PARK, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food & Drug Administration (FDA)...
-
GLEN ROCK, N.J., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, particularly sleep apneas and...
-
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced topline results from the first part of the Phase 3 ANNEXA™-R (Andexanet Alfa a...